The transaction is expected to close in the third quarter of this year and generate $286 million. Some of the product lines that Teleflex will divest include oxygen and aerosol therapy, active humidification, noninvasive ventilation, and incentive spirometers. These products generated $139 million in revenue in 2020. Teleflex entered the agreement with Medline to pay down debt and drive focus toward achieving long-term goals for the company.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.